0	8	Evidence	evidence	NN
9	12	for	for	IN
13	19	normal	normal	JJ
20	27	vitamin	vitamin	NN
28	29	D	D	NNP
30	38	receptor	receptor	NN
39	48	messenger	messenger	NN
49	60	ribonucleic	ribonucleic	JJ
61	65	acid	acid	NN
66	69	and	and	CC
70	78	genotype	genotype	NN
79	81	in	in	IN
82	92	absorptive	absorptive	JJ
93	107	hypercalciuria	hypercalciuria	NN
107	108	.	.	.

110	120	Absorptive	absorptive	JJ
121	135	hypercalciuria	hypercalciuria	NN
136	137	(	(	(
137	138	a	a	DT
139	152	stone-forming	stone-forming	JJ
153	162	condition	condition	NN
162	163	)	)	)
164	166	is	be	VBZ
167	180	characterized	characterize	VBN
181	183	by	by	IN
184	187	gut	gut	NN
188	203	hyperabsorption	hyperabsorption	NN
204	206	of	of	IN
207	214	calcium	calcium	NN
214	215	,	,	,
216	230	hypercalciuria	hypercalciuria	NN
230	231	,	,	,
232	235	and	and	CC
236	243	reduced	reduce	VBD
244	248	bone	bone	NN
249	256	density	density	NN
256	257	.	.	.

258	266	Inasmuch	inasmuch	RB
267	269	as	as	IN
270	275	these	these	DT
276	284	features	feature	NNS
285	294	implicate	implicate	VBP
295	303	enhanced	enhance	VBN
304	314	calcitriol	calcitriol	NN
315	321	action	action	NN
322	324	in	in	IN
325	328	gut	gut	NN
329	332	and	and	CC
333	337	bone	bone	NN
337	338	,	,	,
339	341	we	we	PRP
342	350	analyzed	analyze	VBD
351	354	the	the	DT
355	362	vitamin	vitamin	NN
363	364	D	D	NNP
365	373	receptor	receptor	NN
374	375	(	(	(
375	378	VDR	VDR	NNP
378	379	)	)	)
380	384	gene	gene	NN
385	387	to	to	TO
388	397	ascertain	ascertain	VB
398	405	whether	whether	IN
406	408	an	an	DT
409	420	abnormality	abnormality	NN
421	423	of	of	IN
424	428	this	this	DT
429	433	gene	gene	NN
434	439	marks	mark	VBZ
440	448	patients	patient	NNS
449	453	with	with	IN
454	464	intestinal	intestinal	JJ
465	480	hyperabsorption	hyperabsorption	NN
481	483	of	of	IN
484	491	calcium	calcium	NN
491	492	.	.	.

493	495	We	we	PRP
496	500	have	have	VBP
501	509	compared	compare	VBN
510	513	the	the	DT
514	523	frequency	frequency	NN
524	526	of	of	IN
527	528	a	a	DT
529	540	restriction	restriction	NN
541	549	fragment	fragment	NN
550	556	length	length	NN
557	569	polymorphism	polymorphism	NN
570	571	(	(	(
571	574	Bsm	Bsm	NNP
575	576	I	i	CD
576	577	)	)	)
578	588	associated	associate	VBN
589	593	with	with	IN
594	603	different	different	JJ
604	611	alleles	allele	NNS
612	614	of	of	IN
615	618	the	the	DT
619	622	VDR	VDR	NNP
623	627	gene	gene	NN
628	630	in	in	IN
631	632	a	a	DT
633	638	group	group	NN
639	641	of	of	IN
642	644	33	33	CD
645	649	well	well	RB
650	663	characterized	characterize	VBN
664	674	absorptive	absorptive	JJ
675	689	hypercalciuric	hypercalciuric	JJ
690	698	patients	patient	NNS
699	702	and	and	CC
703	704	a	a	DT
705	710	group	group	NN
711	713	of	of	IN
714	716	36	36	CD
717	723	normal	normal	JJ
724	729	race-	race-	NN
730	733	and	and	CC
734	745	age-matched	age-matched	JJ
746	753	control	control	NN
754	762	subjects	subject	NNS
762	763	.	.	.

764	769	There	there	EX
770	773	was	be	VBD
774	776	no	no	DT
777	787	difference	difference	NN
788	795	between	between	IN
796	799	the	the	DT
800	812	distribution	distribution	NN
813	815	of	of	IN
816	819	the	the	DT
820	823	VDR	vdr	NN
824	831	alleles	allele	NNS
832	834	in	in	IN
835	838	the	the	DT
839	846	patient	patient	NN
847	857	population	population	NN
858	862	when	when	WRB
863	871	compared	compare	VBN
872	876	with	with	IN
877	880	the	the	DT
881	887	normal	normal	JJ
888	898	population	population	NN
898	899	.	.	.

900	903	The	the	DT
904	910	coding	cod	VBG
911	917	region	region	NN
918	920	of	of	IN
921	924	VDR	VDR	NNP
925	934	messenger	messenger	NN
935	938	RNA	RNA	NNP
939	942	was	be	VBD
943	947	also	also	RB
948	954	normal	normal	JJ
954	955	,	,	,
956	958	as	as	IN
959	969	determined	determine	VBN
970	972	by	by	IN
973	977	both	both	CC
978	981	DNA	DNA	NNP
982	990	sequence	sequence	NN
991	999	analysis	analysis	NN
1000	1003	and	and	CC
1004	1012	chemical	chemical	NN
1013	1021	mismatch	mismatch	NN
1022	1030	cleavage	cleavage	NN
1031	1039	analysis	analysis	NN
1040	1042	of	of	IN
1043	1047	copy	copy	NN
1048	1051	DNA	dna	NN
1052	1056	from	from	IN
1057	1059	11	11	CD
1060	1065	index	index	NN
1066	1076	absorptive	absorptive	JJ
1077	1091	hypercalciuric	hypercalciuric	JJ
1092	1100	patients	patient	NNS
1100	1101	.	.	.

1102	1104	On	on	IN
1105	1108	the	the	DT
1109	1114	basis	basis	NN
1115	1117	of	of	IN
1118	1123	these	these	DT
1124	1131	results	result	NNS
1131	1132	,	,	,
1133	1135	we	we	PRP
1136	1143	propose	propose	VBP
1144	1148	that	that	IN
1149	1152	the	the	DT
1153	1161	enhanced	enhance	VBN
1162	1172	intestinal	intestinal	JJ
1173	1180	calcium	calcium	NN
1181	1191	absorption	absorption	NN
1192	1202	invariably	invariably	RB
1203	1207	seen	see	VBN
1208	1210	in	in	IN
1211	1221	absorptive	absorptive	JJ
1222	1236	hypercalciuria	hypercalciuria	NN
1237	1240	and	and	CC
1241	1250	attendant	attendant	JJ
1251	1259	symptoms	symptom	NNS
1260	1262	of	of	IN
1263	1267	this	this	DT
1268	1276	disorder	disorder	NN
1277	1280	are	be	VBP
1281	1284	not	not	RB
1285	1297	attributable	attributable	JJ
1298	1300	to	to	TO
1301	1310	mutations	mutation	NNS
1311	1313	of	of	IN
1314	1317	the	the	DT
1318	1321	VDR	vdr	NN
1322	1325	and	and	CC
1326	1329	are	be	VBP
1330	1333	not	not	RB
1334	1340	linked	link	VBN
1341	1343	to	to	TO
1344	1345	a	a	DT
1346	1352	common	common	JJ
1353	1356	VDR	vdr	NN
1357	1365	genotype	genotype	NN
1365	1366	.	.	.